Prothena to Host Update on PRX003 Phase 2 Development Strategy
(Thomson Reuters ONE) -
DUBLIN, Ireland, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc
(NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the
discovery, development, and commercialization of novel protein immunotherapies,
today announced that members of its management team will discuss the Phase 2
development strategy for PRX003, the antibody in development for the potential
treatment of inflammatory diseases, including psoriasis, during a webcast on
September 29.
Conference Call and Webcast Details
Prothena management will provide an overview of PRX003, a novel antibody that
targets CD146 (or melanoma cell adhesion molecule, MCAM) and discuss its Phase
2 development strategy during a live audio webcast and conference call on
September 29, 2016, at 4:30 PM EDT. The webcast and slide presentation will be
made available on the company's website at www.prothena.com under the Investors
tab in the Events and Presentations section.
To access the conference call via dial-in, please dial (877) 887-5215 (U.S.
toll free) or (315) 625-3069 (international) five minutes prior to the start
time and refer to conference ID number 83102616. A replay of the webcast and
call will be available for at least 90 days via dial-in at (855) 859-2056 (U.S.
toll free) or (404) 537-3406 (international), Conference ID Number 83102616.
About Prothena
Prothena Corporation plc is a global, late-stage clinical biotechnology company
seeking to fundamentally change the course of progressive diseases with its
clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific
understanding built over decades of research in protein misfolding and cell
adhesion - the root causes of many serious or currently untreatable amyloid and
inflammatory diseases - Prothena has advanced several drug candidates into
clinical trials while pursuing discovery of additional novel therapies. Our
pipeline of antibody-based product candidates targets a number of potential
indications including AL amyloidosis (NEOD001), Parkinson's disease and other
related synucleinopathies (PRX002), inflammatory diseases, including psoriasis
(PRX003), and ATTR amyloidosis (PRX004). For more information, please visit the
company's web site at www.prothena.com.
Contacts
Investors: Tran Nguyen, CFO
650-837-8535, IR(at)prothena.com
Media: Ellen Rose
650-922-2405, ellen.rose(at)prothena.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Prothena Corporation plc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 22.09.2016 - 22:05 Uhr
Sprache: Deutsch
News-ID 496585
Anzahl Zeichen: 3175
contact information:
Town:
DUBLIN
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 305 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prothena to Host Update on PRX003 Phase 2 Development Strategy"
steht unter der journalistisch-redaktionellen Verantwortung von
Prothena Corporation plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
